Molecular therapy for Pulmonary Hypertension (PAH): NR2F2 inhibits pulmonary hypertension via induction of PDLIM5, 09/February/2015, 22.20

Molecular therapy for Pulmonary Hypertension (PAH): NR2F2 inhibits pulmonary hypertension via induction of PDLIM5, 09/February/2015, 22.20

Molecular therapy for Pulmonary Hypertension (PAH): NR2F2 inhibits pulmonary hypertension via induction of PDLIM5, 09/February/2015, 22.20 150 150

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that NR2F2, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “NR2F2 or its activators“ may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How NR2F2  increases the expression of PDLIM5

To cite: Boominathan, Molecular therapy for Pulmonary Hypertension (PAH): NR2F2 inhibits pulmonary hypertension via induction of PDLIM5, 09/February/2015,  22.20,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Share
Start Typing